Stifel Financial Corp Sells 224 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Stifel Financial Corp cut its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,065 shares of the company’s stock after selling 224 shares during the quarter. Stifel Financial Corp’s holdings in Invesco Biotechnology & Genome ETF were worth $912,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth approximately $26,000. UMB Bank n.a. acquired a new position in shares of Invesco Biotechnology & Genome ETF in the second quarter valued at $31,000. Howe & Rusling Inc. bought a new position in Invesco Biotechnology & Genome ETF in the third quarter worth $31,000. Carnegie Investment Counsel acquired a new stake in Invesco Biotechnology & Genome ETF during the third quarter worth $204,000. Finally, Creative Financial Designs Inc. ADV raised its stake in shares of Invesco Biotechnology & Genome ETF by 5.6% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after buying an additional 299 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA:PBE opened at $67.53 on Tuesday. The company has a 50-day moving average of $69.19 and a 200-day moving average of $68.62. Invesco Biotechnology & Genome ETF has a 52 week low of $59.32 and a 52 week high of $72.84. The company has a market capitalization of $272.82 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.